125 related articles for article (PubMed ID: 9719457)
41. Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein.
Sparreboom A; Planting AS; Jewell RC; van der Burg ME; van der Gaast A; de Bruijn P; Loos WJ; Nooter K; Chandler LH; Paul EM; Wissel PS; Verweij J
Anticancer Drugs; 1999 Sep; 10(8):719-28. PubMed ID: 10573204
[TBL] [Abstract][Full Text] [Related]
42. MDR1 and BCRP1 expression in leukemic progenitors correlates with chemotherapy response in acute myeloid leukemia.
Ho MM; Hogge DE; Ling V
Exp Hematol; 2008 Apr; 36(4):433-42. PubMed ID: 18249061
[TBL] [Abstract][Full Text] [Related]
43. Lack of correlation between expression and function of P-glycoprotein in acute myeloid leukemia cell lines.
Bailly JD; Muller C; Jaffrézou JP; Demur C; Gassar G; Bordier C; Laurent G
Leukemia; 1995 May; 9(5):799-807. PubMed ID: 7769842
[TBL] [Abstract][Full Text] [Related]
44. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative.
Hyafil F; Vergely C; Du Vignaud P; Grand-Perret T
Cancer Res; 1993 Oct; 53(19):4595-602. PubMed ID: 8402633
[TBL] [Abstract][Full Text] [Related]
45. A novel method for direct and fluorescence independent determination of drug efflux out of leukemic blast cells.
Schaich M; Neu S; Beck J; Gekeler V; Schuler U; Ehninger G
Leuk Res; 1997 Oct; 21(10):933-40. PubMed ID: 9403004
[TBL] [Abstract][Full Text] [Related]
46. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors.
Profit L; Eagling VA; Back DJ
AIDS; 1999 Sep; 13(13):1623-7. PubMed ID: 10509562
[TBL] [Abstract][Full Text] [Related]
47. MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine.
Drescher S; Schaeffeler E; Hitzl M; Hofmann U; Schwab M; Brinkmann U; Eichelbaum M; Fromm MF
Br J Clin Pharmacol; 2002 May; 53(5):526-34. PubMed ID: 11994059
[TBL] [Abstract][Full Text] [Related]
48. Rapid stimulation of rhodamine 123 efflux from multidrug-resistant KB cells by progesterone.
Jancis EM; Chen HX; Carbone R; Hochberg RB; Dannies PS
Biochem Pharmacol; 1993 Nov; 46(9):1613-9. PubMed ID: 7902090
[TBL] [Abstract][Full Text] [Related]
49. Expression and function of multidrug resistance P-glycoprotein in a cultured natural killer cell-rich population revealed by MRK16 monoclonal antibody and AHC-52.
Kobayashi Y; Yamashiro T; Nagatake H; Yamamoto T; Watanabe N; Tanaka H; Shigenobu K; Tsuruo T
Biochem Pharmacol; 1994 Oct; 48(8):1641-6. PubMed ID: 7980629
[TBL] [Abstract][Full Text] [Related]
50. Flow cytometric analysis of P-glycoprotein function using rhodamine 123.
Pétriz J; García-López J
Leukemia; 1997 Jul; 11(7):1124-30. PubMed ID: 9205001
[TBL] [Abstract][Full Text] [Related]
51. Resistance to spontaneous apoptosis in acute myeloid leukaemia blasts is associated with p-glycoprotein expression and function, but not with the presence of FLT3 internal tandem duplications.
Pallis M; Turzanski J; Grundy M; Seedhouse C; Russell N
Br J Haematol; 2003 Mar; 120(6):1009-16. PubMed ID: 12648071
[TBL] [Abstract][Full Text] [Related]
52. Assessment of P-glycoprotein expression by immunocytochemistry and flow cytometry using two different monoclonal antibodies coupled with functional efflux analysis in 34 patients with acute myeloid leukemia.
Poulain S; Lepelley P; Cambier N; Cosson A; Fenaux P; Wattel E
Adv Exp Med Biol; 1999; 457():57-63. PubMed ID: 10500780
[TBL] [Abstract][Full Text] [Related]
53. Impact of BCRP/MXR, MRP1 and MDR1/P-Glycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cells.
Stein U; Lage H; Jordan A; Walther W; Bates SE; Litman T; Hohenberger P; Dietel M
Int J Cancer; 2002 Feb; 97(6):751-60. PubMed ID: 11857350
[TBL] [Abstract][Full Text] [Related]
54. Influence of sequential exposure to R-verapamil or B8509-035 on rhodamine 123 accumulation in human lymphoblastoid cell lines.
Roller E; Klumpp B; Krause J; Eichelbaum M; Schumacher K
Cancer Chemother Pharmacol; 1993; 32(2):151-5. PubMed ID: 8097969
[TBL] [Abstract][Full Text] [Related]
55. 99Tcm-sestamibi imaging of inhibition of the multidrug resistance transporter in a mouse xenograft model of human breast cancer.
Muzzammil T; Ballinger JR; Moore MJ
Nucl Med Commun; 1999 Feb; 20(2):115-22. PubMed ID: 10088159
[TBL] [Abstract][Full Text] [Related]
56. MDR1 polymorphisms G2677T in exon 21 and C3435T in exon 26 fail to affect rhodamine 123 efflux in peripheral blood lymphocytes.
Oselin K; Gerloff T; Mrozikiewicz PM; Pähkla R; Roots I
Fundam Clin Pharmacol; 2003 Aug; 17(4):463-9. PubMed ID: 12914549
[TBL] [Abstract][Full Text] [Related]
57. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
[TBL] [Abstract][Full Text] [Related]
58. Efficiency of P-glycoprotein-mediated exclusion of rhodamine dyes from multidrug-resistant cells is determined by their passive transmembrane movement rate.
Eytan GD; Regev R; Oren G; Hurwitz CD; Assaraf YG
Eur J Biochem; 1997 Aug; 248(1):104-12. PubMed ID: 9310367
[TBL] [Abstract][Full Text] [Related]
59. Rho(0) tumor cells: a model for studying whether mitochondria are targets for rhodamine 123, doxorubicin, and other drugs.
Hu Y; Moraes CT; Savaraj N; Priebe W; Lampidis TJ
Biochem Pharmacol; 2000 Dec; 60(12):1897-905. PubMed ID: 11108806
[TBL] [Abstract][Full Text] [Related]
60. Rhodamine 123 efflux in human subpopulations of hematopoietic stem cells: comparison between bone marrow, umbilical cord blood and mobilized peripheral blood CD34+ cells.
Wagner-Souza K; Diamond HR; Ornellas MH; Gomes BE; Almeida-Oliveira A; Abdelhay E; Bouzas LF; Rumjanek VM
Int J Mol Med; 2008 Aug; 22(2):237-42. PubMed ID: 18636179
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
